News

Feb. 18, 2021, Hangzhou - SB China Capital (SBCVC) portfolio company New Horizon Health was officially listed on the Hong Kong Stock Exchange on the first working day of Chinese Lunar Year of the Ox, with stock code 6606.HK. New Horizon Health's public offering was 4,133 times oversubscribed, with 76,598,000 shares issued globally. The offer price of the international offering and Hong Kong public offering finally was HK $26.66 per share. By midday, New Horizon Health 's share price has surged over 188%, with a market capitalization of over HK$32 billion. Dr. Hua Ping, Managing Partner of SBCVC, attended the listing celebration ceremony of New Horizon Health in Hangzhou.

SBCVC participated in the round A financing of New Horizon Health in 2016, and continued to add holdings in its subsequent B, C and D rounds of financing. Over the past five years, SBCVC has continued to work with New Horizon Health and deploy resources in the field of cancer early screening.

At 9:30 a.m. local time, Zhu Yeqing, co-founder and CEO of New Horizon Health, and Chen Yiyou, co-founder and chief scientist of New Horizon Health, jointly rang the opening bell. Li Zhilong, Deputy Secretary and District Head of Hangzhou High-tech Zone (Binjiang), Director of Management Committee of Hangzhou High-tech Zone, Professor Zheng Shu, Director of Academic Committee of Zhejiang University Cancer Institute, Zhang Ligang, Founder, Chairman and CEO of Akcome Group, and Professor Ding Kefeng, Vice President of the Second Affiliated Hospital of Zhejiang University School of Medicine, witnessed the listing ceremony on stage.

Dr. Hua Ping (sixth from right), Managing Partner of SBCVC, and representatives of various investment institutions attended the listing ceremony

“From getting the ‘First Certificate of Cancer Early Screening in China’ on November 9, 2020 to the listing of the ‘First Stock of Cancer Early Screening in China’, New Horizon Health has witnessed and promoted the key journey of cancer early screening in China from dream to reality. The listing has opened a new era for New Horizon Health. We still have a long way to go with the same original intention." New Horizon Health co-founder and CEO Zhu Yeqing said, "Our future customers are the hundreds of millions of people with high-risk and average risk in high incidence cancers in China. New Horizon Health hopes to join hands with insightful people in the whole society to continuously promote the popularization of cancer early screening at home, change the life trajectory of more people, and make cancer screening, like medical checkups, become a standard and fairly well-known configuration of personal health management."

According to Chen Yiyou, Co-Founder and Chief Scientist of New Horizon Health, funds from this fundraising will be used for the large-scale commercialization and further development of its star product Coloclear®; the continued sales and marketing of Pupu Tube® and additional clinical evaluations of Coloclear® and Pupu Tube® in different populations; product development to further enrich the company's product line; potential acquisitions or external introduction of product candidates and for general corporate purposes.

As of September 30, 2020, New Horizon Health has covered about 119 cities, 235 medical checkup centers, 36 insurance companies, 316 hospitals and clinics, 457 pharmacies, 78 online platforms, sales team with more than 1,000 outsourced sales staff, and more than 40 research institutions in China. New Horizon Health got the " First Certificate of Cancer Early Screening in China" on November 9, 2020.

The data shows that in 2020, the number of new cancer cases and deaths worldwide is 19.29 million and 9.96 million respectively. Among them, the number of new cancer cases and deaths in China is 4.57 million and 3 million, accounting for 23.7% and 30% of the global total. These two numbers are ranked first in the world. Because the people targeted for early cancer screening are “healthy” people who have not yet shown symptoms, the market potential is huge. For colorectal cancer early screening alone, the market may exceed 10 billion per year. With the scale effect and cost advantage of first mover in this field, New Horizon Health has huge space for future development.

About New Horizon Health

Founded in 2015, New Horizon Health focuses on early home screening for high-incidence cancers and is a pioneer and leader in the Chinese cancer screening market. The company aims to advance innovation in cancer screening technology and accelerate the spread of cancer screening technology in China. New Horizon Health's two colorectal cancer screening products (Coloclear® and Pupu Tube®) have been approved by State Food and Drug Administration (SFDA) in China and are now commercially available. Coloclear® is the first and currently the only cancer screening product approved by the SFDA in China. In addition, New Horizon Health has two product lines in development for gastric and cervical cancer screening respectively. New Horizon Health holds global ownership of all its marketed products and products under development.